HelpHelp About Us Contact Contact Us Help Help
Press Release Service
user name password
Client login:   
First time user sign up Forgot your login info?
Website Directory     Submit Website

Search
EmailWire News Links

Home > News By Company > LegalView

Print e mail rss del Y! myWeb Tweet
 

LegalView Announced its Newest Information Portal with Details of the Digitek Digoxin Heart Tablet Recall

LegalView informed readers of its newest information portal detailing the U.S. Food and Drug Administration (FDA) ordered recall of the Digitek-brand digoxin heart tablets. The tablets had been recently discovered to have been manufactured containing twic

(EMAILWIRE.COM, May 20, 2008 ) Denver, CO - LegalView, the most comprehensive resource available for everything legal on the Web, announces the development of the Digitek digoxin (http://digitek-digoxin.legalview.com) information portal, which was created after the U.S. Food and Drug Administration (FDA) issued warnings of potential risks associated with improper manufacturing. The Digitek recall (http://digitek-digoxin.legalview.com) occurred en reports surfaced with information that some batches of Digitek digoxin contained double the appropriate amount of active ingredient. Digitek digoxin is a heart tablet that treats an array of heart rate irregularities such as atrial fibrillation (cardiac arrhythmia), atrial flutter (abnormal heart rhythm), abnormal heart rhythms and heart failure. Often, when these conditions are not treatable by other medications, a patient will receive a prescription for digoxin.

However, the excessive amount of active ingredient in the drug can cause digoxin toxicity (http://digitek-digoxin.legalview.com), putting patients at risk for renal failure and potentially death. In many instances Digitek digoxin has also caused patients to suffer from digoxin side effects (http://digitek-digoxin.legalview.com), which can consist of vomiting, dizziness, nausea, low blood pressure and cardiac instability, according to the FDA. Individuals who have taken the botched batch of Digitek digoxin may be at risk for digitalis toxicity (http://digitek-digoxin.legalview.com), which can result in death, and should contact a medical profession immediately. Patients are also advised to consult with a pharmaceutical lawyer for more information on developing a Digitek lawsuit (http://digitek-digoxin.legalview.com) to retrieve potential monetary compensation for the pain and suffering caused.

Additionally, LegalView offers information on other controversial prescription drugs including Chantix and Heparin. Chantix, a smoking cessation drug, was released to the market in May 2006 and had reportedly been prescribed to nearly 3 million Americans attempting to quit smoking. Reports began to surface in late 2007 about the Chantix side effects (http://chantix.legalview.com), which consisted of depression, erratic behavior, and suicidal thoughts and tendencies. Nearly 400 incidents of these side effects were reported to the FDA and approximately 38 suicides before the drug was recalled.

Finally, LegalView offers the most up-to-date news on the Heparin controversy for readers and victims of the Heparin recall. Heparin is a blood thinner injected into patients undergoing surgical procedures, usually heart-related procedures. It is used to prevent the development of blood clots, which are often deadly among surgical patients. A rash of allergic reactions began to appear in patients who had received Baxter's Heparin and it was soon discovered that the drug contained a contaminant that FDA officials allege had derived from a Chinese manufacturing plant. However, Chinese health officials continue to maintain their innocence and insist the drug's contamination occurred on U.S. soil. While victims continue to suffer from the after affects of the Heparin contamination, officials seemingly do nothing but point fingers. Patients who received this drug should speak with a pharmaceutical attorney at once to learn about developing a Heparin lawsuit, http://baxter-heparin.legalview.com.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.

###

This press release was issued through GroupWeb EmailWire.Com. For more information on unlimited press release distribution service, go to http://www.emailwire.com

Contact Information:
LegalView
Katie Kelley
Tel: 720-771-3246
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Press Release Keywords:

Digitek, Digoxin, Digitek brand, heart tablets, lawyer, law firm, lawsuit, attorney, legal consultation, Digitek recall, Digoxin recall, digoxin recall lawyer, digoxin recall law firm, digoxin recall attorney, digoxin recall lawsuit, Digi

Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International

Equityallianceir.com





Penny Stocks to Watch

Sign up for hot penny stock picks
Gains of 500%+ possible!

Premiumstockpicks.com/landing/




Your text Ads & 

PR

Text Ads plus unlimited press releases, One release featured/Day for only $575 per month.

Read more on Text Ads & PR






Your text Ads Here!

Text Ads are only $289 per month. Ads are placed same day.

More on Text Ads Advertising




 

Search


Advertising | How to contact us | Privacy Statement | EmailWire Press Releases | Partnership Opportunities

EmailWire is a press release distribution service of GroupWeb Media LLC.

© Copyright GroupWeb Media LLC 2012